Antibody-mediated Rejection in Kidney Transplant

Assess Burden of Disease Among Kidney Transplant Recipients With Chronic Active Antibody Mediated Rejection

NCT05452317 | OBSERVATIONAL

This study investigates the burden of disease among kidney transplant recipients that have developed Chronic Active Antibody Mediated Rejection (caAMR) compared with kidney transplant recipients that have not developed caAMR

3 Sites

52 Participants

COMPLETED

18 Years

If interested, contact clinicaltrials@cslbehring.com or +1 610-878-4697 for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Find closest sites:

SUBMIT

Keck Medical Center of USC

Los Angeles,California,United States,90033

University of Maryland School of Medicine, Div. of Nephrology

Baltimore,Maryland,United States,21201

The Washington University

Saint Louis,Missouri,United States,63130

Study Eligibility Criteria

Inclusion Criteria

Chronic Active AMR group:
* 18 Years and older
* Recipient of blood group system (ABO) compatible solitary kidney transplant between \[1Jan2013\] and \[1Jan2018\]
* Chronic active AMR diagnosed via kidney biopsy based upon Banff criteria. Patients who additionally have diagnoses such as TCMR, acute tubular necrosis, recurrence of primary kidney disease are also eligible if not the predominant pathology.
* DSA antibodies within prior 6 months of the biopsy which confirmed chronic active AMR
* Minimum of 3 years of follow up data following diagnosis of chronic active AMR (unless patient had died)
* eGFR at time of diagnosis of chronic active AMR of \>25ml/min/1.73m2
Non-Chronic active AMR group:
* Age 18 years or older
* Recipient of ABO compatible solitary kidney transplant between \[1 Jan 2013\] and \[1Jan2018\]
* No documented diagnosis of chronic active AMR during the data extraction period. Patients with other diagnoses such as TCMR, acute tubular necrosis, recurrence of primary kidney disease are also eligible. Patients may or may not have had biopsies.
* Minimum of 4 years of follow up data since transplant (unless patient has died)
* eGFR of \>25ml/min/1.73m2 at time of matching

Exclusion Criteria

Chronic active AMR group:
* Recipient of a multi-organ transplant
* ABO-incompatible transplant
* Patient lost to follow up within the first 3 years post-diagnosis of chronic active AMR and whose allograft status (graft failure or patient death) is unknown.
Non-Chronic active AMR group:
* Recipient of a multi-organ transplant
* ABO-incompatible transplant
* Patient lost to follow up within the first 4 years of transplant and whose allograft status (graft failure or patient death) is unknown.

Additional Studies

Additional studies can be found at ClinicalTrials.gov